Four years after it was founded, Kymera Therapeutics said Thursday that it has now raised more than a quarter-billion dollars from investors keen on its potential approach to treat a range of diseases, including blood cancers.
The Cambridge, Mass., biotech shared the total after announcing that it had closed a third round of venture capital fundraising that totaled $102 million.The privately held startup plans to begin clinical trials of at least three drugs by next year.
